MEDESIS PHARMA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.39 EUR | -1.42% |
|
+15.83% | +60.14% |
| 2023 | Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | MEDESIS : Invest Securities confirms its recommendation | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 95.73K 103K | Sales 2022 | 197K 212K | Capitalization | 8.68M 9.34M |
|---|---|---|---|---|---|
| Net income 2021 | -2M -2.15M | Net income 2022 | -2M -2.15M | EV / Sales 2021 | 219 x |
| Net cash position 2021 | 1.61M 1.73M | Net Debt 2022 | 1.08M 1.16M | EV / Sales 2022 | 49.4 x |
| P/E ratio 2021 |
-8.52
x | P/E ratio 2022 |
-3.16
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 80.97% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -1.42% | ||
| 1 week | +15.83% | ||
| Current month | +12.10% | ||
| 1 month | +0.72% | ||
| 3 months | +80.52% | ||
| 6 months | +54.44% | ||
| Current year | +60.14% |
1 week
1.23
1.61
1 month
1.141.61
Current year
0.752.40
1 year
0.752.67
3 years
0.7510.10
5 years
0.7518.00
10 years
0.7518.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 03-04-02 | |
Solene Guilliot
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Mario Alcaraz
SEC | Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 19-06-11 | |
Robert Alonso
BRD | Director/Board Member | - | 22-10-26 |
Walt Linscott
BRD | Director/Board Member | 63 | 22-10-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.39 | -1.42% | 876 |
| 24-05-09 | 1.41 | +2.55% | 220 |
| 24-05-08 | 1.375 | +3.00% | 4,325 |
| 24-05-07 | 1.335 | -4.64% | 5,533 |
| 24-05-06 | 1.4 | +16.67% | 36,447 |
Real-time Euronext Paris, May 10, 2024 at 05:23 am EDT
More quotes
Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment.
The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).
| 1st Jan change | Capi. | |
|---|---|---|
| +60.14% | 6.63M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ALMDP Stock